Neuroscience

Woman having epileptic fit
#CHMP #epilepsy #Europe #Neuroscience #Rare disease

Treatment for severe form of epilepsy approved in Europe

UCB’s Fintepla (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy.  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion… Read More

#News #Regulatory

Human neurone
#Biosciences #Genetic diseases #Ion channels #Neurology #Neuroscience #Rare disease #Therapeutics

Ion channel modulators for ultra-rare genetic disorder 

Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra-rare genetic disorder, have entered a collaboration to progress a hit identification research project for small molecule modulators of the potassium… Read More

#News

#Alzheimer's #Neurodegenerative disorders #Neuroscience

Novel peptide targets early molecular trigger of Alzheimer’s

A new study has demonstrated the ability of a novel peptide to selectively detect and neutralise an early molecular trigger of Alzheimer’s and other neurodegenerative diseases.  The Proceedings of the National Academy of Sciences (PNAS) will publish results of the groundbreaking study demonstrating a customised,… Read More

#Editor's Choice #News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

Psychiatrist with patient
#Major depressive disorder #Neuroscience #Phase I trial

Injectable drug could offer new option for depressive disorders

The first subject has been dosed in a Phase I biomarker study of apimostinel, a rapid-acting N-methyl-D-aspartate receptor (NMDAR) modulator for major depressive disorders (MDD).  The injectable treatment was developed by clinical-stage biotechnology company Gate Neurosciences for acute depressive disorders… Read More

#News #Trending News

MRI of the brain
#epilepsy #Mouse models #Neuroinflammation #Neuroscience

Neuroscientists discover new drug candidate for treating epilepsy

Neuroscientists have identified and developed a new drug candidate that has the potential to effectively treat temporal lobe epilepsy (TLE) by suppressing neuroinflammation.  Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. Most of these… Read More

#News #Trending News

Discovery Park, Kent
#Life sciences #Neuroscience #Pfizer #Science and innovation park

UK Discovery Park plans centre of excellence for neuroscience

One the UK’s largest science and innovation parks has revealed plans to double in size as it celebrates its ten-year anniversary. Discovery Park, based near Sandwich in Kent, marked the milestone by announcing its plans for the next ten years, which include the creation of a national centre of excellence… Read More

#News

#Covid-19 #Geographic atrophy #Immunology / Virology & Vaccines #Malaria #Neuroscience #Psychedelics

Catch up on the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a week that saw magic mushrooms making the… Read More

#News

#Interview #Mental health #Neuroscience #Precision psychiatry #Psychiatry #Psychiatry Consortium #Target identification #Target validation

Target validation in psychiatry: addressing unmet therapeutic needs

The Psychiatry Consortium and the British Neuroscience Association recently published their 'Guiding Principles for Robust Target Validation in Psychiatry'. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic… Read More

#Exclusive Content

Neurons in the brain
#Antidepressants #Interview #Major depressive disorder #Neuropsychiatric disorders #Neuroscience #Precision medicine #Precision psychiatry #Psychiatry

Precision psychiatry: Transforming therapeutics for CNS disorders

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our understanding… Read More

#Exclusive Content

#AI #Artificial intelligence (AI) #Brain disease #Nervous system disorders #Neuroscience #Neurotechnology

Keeping technology at the front of neuroscience research 

Listen to this article on the DDW Podcast: David Gray, CSO of Inscopix talks to Lu Rahman about the company’s understanding of the neuroscience market and its quest to improve technologies for neuroscientists to enable multimodal research.  Inscopix is a neurotechnology company focused on understanding the function of the brain to… Read More

#Exclusive Content

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

Patient reported outcomes
#Biomarkers #Mental health #Neurodegenerative disorders #Neurology #Neuroscience #Psychiatry

The rise of digital biomarkers in neuroscience drug development 

Listen to this article on the DDW Podcast: Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.  Increasingly, digital biomarkers are becoming more effectively used in the discovery and… Read More

#Editor's Choice #Exclusive Content

#Alzheimer's #Drug discovery #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Tau protein

Taking a new approach to tackle neurodegenerative diseases

Listen to this article on the DDW Podcast: William Erhardt, President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases.  New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by… Read More

#Editor's Choice #Exclusive Content

#Collaboration #Drug therapy #Neuroscience #Parkinson's

Collaboration targeting neuroinflammation to slow Parkinson’s  

Parkinson’s UK and Domainex have collaborated to develop small molecule therapies targeting neuroinflammation that could slow the progression of Parkinson’s Disease.   Context  Inflammation is vital for defending the body from infections, injuries and toxins. However, in Parkinson’s there is excessive chronic inflammation within the brain. Read More

#News